Blog

June 25, 2021June 25, 2021

El Cercle d’Economia Grants David Pellicer, CEO of Etnia Barcelona, the José Manuel Lara Award

Etnia Barcelona has won the most widely recognized national business award in Spain, the José Manuel Lara Award. The prestigious award is made in remembrance of José Manuel Lara Bosch.

The awards ceremony was held last Thursday, June 17 as part of the Economic Symposium. The award made by the Cercle d’Economia, acknowledges the passage of an enterprise from infancy to maturity.

David Pellicer thanked the Cercle d’Economia and jury, as well as appreciating the contribution of his own team. He underscored the effort and tenacity required to make a dream like his come true, to stand as a model to the sector. Likewise, he made a call for the need to “do something of significance”, to leave a legacy for the future.

Etnia Barcelona, which will be celebrating its 21^st anniversary this year, is ranked between third and second place in terms of the brands that sell most in Europe. From the very outset, its success has been built around top-quality design and end-to-end control of the entire creative process. The use of colour in all its designs has resulted in it owning the most colour references of any firm in the eyewear sector.

With offices in Barcelona, Miami, Vancouver, and Hong Kong, it has a presence in over 60 countries, 15,000 points of sale worldwide. It boasts a spectacular Flagship Store in the emblematic Born District of Barcelona featuring 7 storeys dedicated to eyewear culture, showcasing the absolute best of the brand.

Click HERE for the full press release.

Marketing4ECPs Completes Acquisition of Innexus

Marketing4ECPs, a provider of vertically-focused digital marketing solutions, has announced the acquisition of Innexus, a company that specializes in eye care practice marketing – providing clients with a full suite of solutions, including website design, social media, and digital advertising.

“We are pleased to join forces with Innexus – a team of highly specialized eye care marketing experts to the Marketing4ECPs family,” said Kevin Wilhelm, Marketing4ECPs Co-Founder and CEO. “We share the same passion for supporting the growth and profitability of eye care practices across North America. Our core values, purpose, and vision align as organizations. We are pleased to merge our network of resources and expertise for our mutual clients”.

Innereactive, the parent company of Innexus, was founded in 2003, by industry expert, speaker Samantha Toth. While Innereactive will remain under full ownership by Toth, the separate division of Innexus that began in 2009 will become part of the Marketing4ECPs family. “The decision to split Innereactive and Innexus into two separate divisions was difficult, but I’m extremely excited for both the team and members of Innexus to have the opportunity to join the Marketing4ECPs family. A lot of purposeful thought and collaboration went into this decision, and I couldn’t be happier to have found the right home for Innexus”, says Toth.

Innereactive will continue to operate independently of Innexus and service enterprise clients in the eye care industry under the leadership of Samanth Toth.

According to the press release, Innexus has helped over a thousand eye care practices across North America grow their patient bases, brand recognition, and overall profitability.

The acquisition of Innexus further strengthens Marketing4ECPs’ position within the eye care industry. “We maintain our ongoing commitment to providing the industry with innovative marketing solutions, world-class customer service, thought-leadership, and guidance of the ever-changing marketing landscape”, says Trudi Charest, Co-Founder of Marketing4ECPs.

Reference Links:
Marketing4ECPs: www.marketing4ecps.com
Innexus: www.getinnexus .com

June 23, 2021May 20, 2026

AYA’s Dixon is Chic with Its Ojibwe Bear Design

Dixon’s stately angles and bold brow bar are a modern take on a very retro frame.
Dixon is highlighted with a dynamic bear design by Donald Chretien. The bear clan has
significance in Ojibwe culture. Available in chic matte black and shiny gold, matte blue
and silver, and satin red and black.

Distributed by: www.claudiaalan.com

June 23, 2021June 22, 2021

CooperVision Specialty EyeCare Announces Uniform Markings Across Blanchard Onefit Family of Scleral Lenses

CooperVision Specialty EyeCare announced that lens markings are now uniform across the entire Blanchard Onefit™ family of scleral lenses, including Onefit™ MED and Onefit™ MED+. The uniform markings for front torics and toric haptics across the Onefit™ family aid in distinguishing whether quadrant specific landing zones and/or limbal zones have been indicated, thereby streamlining the fitting process for eye care professionals (ECPs). If quadrant specific landing zones have been indicated, the values for all four quadrants will be etched into each lens.

“We are committed to producing the highest-quality scleral lenses for the benefit of both the patient and the eye care professional,” said Marie-Christine Blanchard, Global Lead, Scleral and Irregular Cornea category for CooperVision Specialty EyeCare, Americas. “With the innovative lens design features of our Onefit™ MED and Onefit™ MED+, we are making ECPs’ lives easier. This is one of several ways we are strengthening clinical relationships and enhancing our support for the specialty eye care community.”

Further simplifying the fitting process with Onefit™ MED and Onefit™ MED+ lenses, CooperVision Specialty EyeCare has also expanded the Quadrant Specific fitting tool within its online custom tools to provide a visual depiction of the lens markings that will be seen on the final lens.

Click HERE for the full press release.

AMD Clinical Trial Update on Next-GEN Anti-VEGF Treatment

Roche has released the results of a Phase 3 trial of a next-generation anti-VEGF treatment, faricimab, for wet age-related macular degeneration (wet AMD). Anti-VEGF treatments work by blocking the VEGF molecule which promotes uncontrolled blood vessel growth in diseases like diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD).

Faricimab is different because in addition to blocking VEGF, it also blocks a molecule called angiopoetin-2 (Ang-2) which also promotes blood vessel growth. There is hope is that this new treatment might be more potent than traditional anti-VEGFs because it’s attacking the problem (blood vessel growth) in two different ways. In brief, this trial showed that faricimab was as effective as another anti- VEGF (aflibercept (Eylea®)) treatment in maintaining or improving vision for patients newly diagnosed with wet AMD. 45% of patients taking faricimab were able to wait 16 weeks in between injections.

This suggests that some patients diagnosed with wet AMD may have a new treatment option that could reduce how frequently they need to get anti-VEGF injections. Importantly, there were no unexpected negative side effects. Based on the strength of this data, Roche will be submitting faricimab for approval starting with the FDA in the U.S.